WALNUT CAP (00905) issues a profit warning, expecting a mid-term net loss attributable to shareholders to increase by approximately 63% to 68% year-on-year.
Huatai Capital (00905) announced that it expects the loss attributable to owners of the company for the six months ending June 30, 2026 (the first half of 2026) will increase by approximately 63% to 68%, compared to the loss attributable to owners of the company of HKD 26.7 million for the six months ending June 30, 2025.
WALNUT CAP (00905) announced that it expects the attributable loss to owners of the company for the six months ending June 30, 2026 (the first half of 2026) to increase by approximately 63% to 68% compared to the attributable loss to owners of the company of HKD 26.7 million for the six months ending June 30, 2025.
The increase in loss is primarily attributable to: increased losses from the sale of cryptocurrencies; increased losses resulting from fair value changes of financial assets measured at fair value through profit or loss; and a decrease in interest income generated from cryptocurrencies, which was partially offset by a reduction in administrative and other operating expenses.
Related Articles

China Rare Earth Nonferrous Metals (600259.SH) plans to list and transfer a 37% equity stake in Dongdianhua Company, focusing on its core business.

Golden Bridge Group Holdings (00623) issues a profit warning, expecting a mid-term consolidated net profit of approximately 290 million to 320 million yuan.

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd (000766.SZ): Plans to acquire the controlling stake in Bajia Pharmaceutical to deepen its layout in the field of neurological diseases.
China Rare Earth Nonferrous Metals (600259.SH) plans to list and transfer a 37% equity stake in Dongdianhua Company, focusing on its core business.

Golden Bridge Group Holdings (00623) issues a profit warning, expecting a mid-term consolidated net profit of approximately 290 million to 320 million yuan.

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd (000766.SZ): Plans to acquire the controlling stake in Bajia Pharmaceutical to deepen its layout in the field of neurological diseases.

RECOMMEND





